Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437844 | PMC |
| http://dx.doi.org/10.18553/jmcp.2009.15.1.62 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Catheter-Based Radiofrequency Renal Denervation in the United States: A Cost-Effectiveness Analysis Based on Contemporary Evidence.
J Soc Cardiovasc Angiogr Interv
October 2024
Wing Tech Inc, Menlo Park, California.
Background: Catheter-based radiofrequency renal denervation (RF RDN) has recently been approved as an adjunctive treatment for hypertensive patients without adequate blood pressure control. This study assessed the cost-effectiveness of RF RDN in the United States based on contemporary clinical evidence.
Methods: A decision-analytic Markov model projected costs, quality-adjusted life years (QALY), and clinical events for an active cohort treated with RF RDN and a control cohort treated with standard-of-care (defined as 1, 2, or 3 antihypertensive medications).
Efficacy and Safety of Ultrasound Renal Denervation on Office Blood Pressure of Patients with Resistant Arterial Hypertension: A Systematic Review and Meta-analysis.
High Blood Press Cardiovasc Prev
November 2024
University of Sao Paulo Heart Institute, São Paulo, Brazil.
Article Synopsis
- Resistant arterial hypertension (RAH) is a significant global health issue linked to increased cardiovascular risk, and the effectiveness of ultrasound renal denervation (uRDN) as a treatment is not fully understood.
- This study analyzed data from five trials involving 709 patients to evaluate the impact of uRDN on reducing both systolic and diastolic blood pressure in those with RAH.
- Results indicated that uRDN significantly lowered office blood pressure levels compared to sham treatments, though more research is necessary to fully assess its efficacy in managing RAH.
Association of mid-regional pro-adrenomedullin with office and 24-h ambulatory blood pressure in a Swiss general population sample.
J Hypertens
December 2024
Department of Epidemiology and Health Systems, Unisanté.
Objective: Adrenomedullin (ADM) is a potent vasodilator. The association between plasma ADM levels and blood pressure (BP) remains unclear. We assessed the association between mid-regional-pro-ADM (MR-proADM) and BP in a multicenter population- and family-based cohort.
View Article and Find Full Text PDFResistant Hypertension: A Brief Review of Pathophysiology.
J Gen Intern Med
October 2024
Department of Internal Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA.
Article Synopsis
- A 52-year-old man visits his internal medicine clinic for high blood pressure management, having been diagnosed with hypertension 5 years ago, and is also dealing with obesity and high cholesterol.
- Despite taking multiple medications, his blood pressure remains high, indicating resistant hypertension, which often comes with other health issues like obesity and sleep apnea.
- The study discusses the evolving understanding of the causes of resistant hypertension and looks into four key areas: the sympathetic nervous system, aldosterone levels, blood vessel function, and inflammation, along with new treatments being researched.
Impact of expected blood pressure reduction on patient preferences for pharmaceutical and renal denervation treatment.
J Hypertens
February 2025
Piedmont Heart Institute, Atlanta, Georgia, USA.
Background: Effective patient-centered care requires an adequate understanding of patient preferences for different therapeutic options. We modelled patient preference for blood pressure (BP) management by pharmaceutical or interventional treatments such as renal denervation in patients with different profiles of uncontrolled hypertension.
Methods: Modeling was based on the findings from a previously conducted quantitative discrete choice experiment (DCE).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!